



16085 U.S. PTO

**Practitioner's Docket No. 48292 DIV II (47927)**

*PATENT*

### Preliminary Classification:

### **Proposed Class:**

Subclass:

NOTE: "All applicants are requested to include a preliminary classification on newly filed patent applications. The preliminary classification, preferably class and subclass designations, should be identified in the upper right-hand corner of the letter of transmittal accompanying the application papers, for example 'Proposed Class 2, subclass 129.'" M.P.E.P. Section 601, 7th ed.

22141 U.S.PTO  
10/608618

103003

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Box Patent Application  
Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450**

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) AND 1.10\***

*(When using Express Mail, the Express Mail label number is mandatory;  
Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

✓ [ ] deposited with the United States Postal Service in an envelope addressed to: MAIL STOP: PATENT APPLICATION,  
The Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

with sufficient postage as first class mail.  as "Express Mail Post Office to Address"  
Mailing Label No. EV 317952825 US

## TRANSMISSION

[ ] transmitted by facsimile to the Patent and Trademark Office (703) \_\_\_\_\_

Date: October 20, 2003

80

**Signature** Rachelle Chey

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. Section 1.10(b).

*"Since the filing of correspondence under [Section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition."* Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

## NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of:

Inventor(s): **Stina GESTRELIUS, Lars HAMMARSTRÖM, Petter LYUNGSTADAAS, Christer ANDERSSON, Ivan SLABY, and Tomas HAMMARGREN**

**WARNING:**      *37 C.F.R. Section 1.41(a)(1) points out:*

*"(a) A patent is applied for in the name or names of the actual inventor or inventors.*

*(1) The inventorship of a nonprovisional application is that inventorship set forth in the oath or declaration as prescribed by Section 1.63, except as provided for in Section 1.53(d)(4) and Section 1.63(d). If an oath or declaration as prescribed by Section 1.63 is not filed during the pendency of a nonprovisional application, the inventorship is that inventorship set forth in the application papers filed pursuant to Section 1.53(b), unless a petition under this paragraph accompanied by the fee set forth in Section 1.17(i) is filed supplying or changing the name or names of the inventor or inventors."*

For (title): **MATRIX PROTEIN COMPOSITIONS FOR TREATING INFECTION**

### 1. Type of Application

This new application is for a(n)

*(check one applicable item below)*

- Utility (nonprovisional)
- Design
- Plant

**NOTE:** *If one of the following 3 items apply, then complete and attach ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF A PRIOR U.S. APPLICATION CLAIMED and a NOTIFICATION IN PARENT APPLICATION OF THE FILING OF THIS CONTINUATION APPLICATION.*

- Divisional.
- Continuation.
- Continuation-in-part (C-I-P).

**2. Benefit of Prior U.S. Application(s) (35 U.S.C. Sections 119(e), 120, or 121)**

The new application being transmitted claims the benefit of prior U.S. application(s). This application is a Divisional application of United States Serial No. 10/156,300, filed May 28, 2002, which is a Divisional of United States Serial No. 09/258,613, filed February 26, 1999, which is a continuation-in-part of U.S. Provisional Application 60/081,551, filed April 13, 1998. The entireties of these applications are incorporated by reference herein.

**3. Papers Enclosed**

**A. Required for Filing Date under 37 C.F.R. Section 1.53(b) (Regular) or 37 C.F.R. Section 1.153 (Design) Application**

69 Pages of Specification

7 Pages of Claims

12 Sheets of Drawing

Formal  
 Informal

**4. Additional Papers Enclosed**

4 Pages of declaration and power of attorney

1 Pages of Abstract

\_ Other

Cancel in this applications claims \_\_\_\_\_ before calculating the filing fee.  
(At least one original independent claim must be retained for filing purposes.)

Add the claims shown on the attached amendment (claims \_\_\_\_\_).  
(Claims added have been numbered consecutively following the highest numbered original claims.)

Preliminary Amendment  
 Information Disclosure Statement (37 C.F.R. Section 1.98)  
 Form PTO-1449 (PTO/SB/08A and 08B) (**copy from parent application**)  
 Citations (**provided in parent application**)  
 Declaration of Biological Deposit  
 Submission of "Sequence Listing," **2** pages computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence. (**computer readable form (CRF) in parent application, see Preliminary Amendment requesting transfer of CRF from parent application**).  
 Authorization of Attorney(s) to Accept and Follow Instructions from Representative  
 Special Comments

Other

**5. Declaration or Oath (including power of attorney)**

Enclosed (copy from parent application)

Executed by

*(check all applicable boxes)*

inventor(s).

legal representative of inventor(s). 37 C.F.R. Section 1.42 or 1.43.

joint inventor or person showing a proprietary interest on behalf of inventor who refused to sign or cannot be reached.

This is the petition required by 37 C.F.R. Section 1.47 and the statement required by 37 C.F.R. Section 1.47 is also attached. See item 13 below for fee.

Not Enclosed.

Application is made by a person authorized under 37 C.F.R. 1.41 on behalf of *all* the above named inventor(s).

*(The declaration or oath, along with the surcharge required by 37 C.F.R. Section 1.16(e), can be filed subsequently).*

Showing that the filing is authorized.

*(not required unless called into question. 37 C.F.R. Section 1.41(d))*

**6. Inventorship Statement**

**WARNING:** *If the named inventors are each not the inventors of all the claims an explanation, including the ownership of the various claims at the time the last claimed invention was made, should be submitted.*

The inventorship for all the claims in this application are:

The same.

or

Not the same. An explanation, including the ownership of the various claims at the time the last claimed invention was made,  
 is submitted.  
 will be submitted.

**7. Language**

**NOTE:** An application including a signed oath or declaration may be filed in a language other than English. An English translation of the non-English language application and the processing fee of \$130.00 required by 37 C.F.R. Section 1.17(k) is required to be filed with the application, or within such time as may be set by the Office. 37 C.F.R. Section 1.52(d).

English  
 Non-English

The attached translation includes a statement that the translation is accurate. 37 C.F.R. Section 1.52(d).

## 8. Assignment

An assignment of rights to the invention to Biora BioEx AB  
 was recorded in 10/156,300 at Reel No. 012941, Frame 0758 on May 29, 2002.  
 will follow.

**NOTE:** "If an assignment is submitted with a new application, send two separate letters-one for the application and one for the assignment" Notice of May 4, 1990 (1114 O.G. 77-78).

**WARNING:** A newly executed "STATEMENT UNDER 37 C.F.R. Section 3.73(b)" must be filed when a continuation-in-part application is filed by an assignee. Notice of April 30, 1993, 1150 O.G. 62-64.

## 9. Certified Copy

Certified copy(ies) of application(s) (provided in parent application)

<u>Denmark</u>	<u>0270/98</u>	<u>27 February 1998</u>
Country	Appln. no.	Filed
<u>Denmark</u>	<u>PA 1998 01328</u>	<u>16 October 1998</u>
Country	Appln. no.	Filed
Country	Appln. no.	Filed

**NOTE:** The foreign application forming the basis for the claim for priority must be referred to in the oath or declaration. 37 C.F.R. Section 1.55(a) and 1.63.

**NOTE:** This item is for any foreign priority for which the application being filed directly relates. If any parent U.S. application or International Application from which this application claims benefit under 35 U.S.C. 120 is itself entitled to priority from a prior foreign application, then complete item 18 on the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

## 10. Fee Calculation (37 C.F.R. Section 1.16)

A.  Regular application

---

CLAIMS AS FILED

---

Claims	Number Filed	Basic Fee Allowance	Number Extra	Rate	Basic Fee 37 C.F.R. Section 1.16(a) \$770.00
--------	--------------	------------------------	--------------	------	---

Total Claims  
(37 C.F.R.  
Section  
1.16(c))

	16	- 20 =	x	\$18.00
--	----	--------	---	---------

---

Independent Claims  
(37 C.F.R. Section  
1.16(b))

	1	- 3 =	x	\$84.00
--	---	-------	---	---------

---

Multiple Dependent  
Claim(s), if any  
(37 C.F.R. Section  
1.16(d))

+ \$280.00

---

[ ] Amendment cancelling extra claims is enclosed.  
[ ] Amendment deleting multiple-dependencies is enclosed.  
[ ] Fee for extra claims is not being paid at this time.

*NOTE: If the fees for extra claims are not paid on filing they must be paid or the claims cancelled by amendment, prior to the expiration of the time period set for response by the Patent and Trademark Office in any notice of fee deficiency. 37 C.F.R. Section 1.16(d).*

Filing Fee Calculation \$ 770.00

B. [ ] Design application  
(\$330.00–37 C.F.R. Section 1.16(f))  
Filing Fee Calculation \$ \_\_\_\_\_

C. [ ] Plant application  
(\$510.00–37 C.F.R. Section 1.16(g))  
Filing Fee Calculation \$ \_\_\_\_\_

11. Small Entity Statement(s)

Pursuant to 37 CFR 1.27, Applicants claim small entity status.

**12. Request for International-Type Search (37 C.F.R. Section 1.104(d))**

*(complete, if applicable)*

Please prepare an international-type search report for this application at the time when national examination on the merits takes place.

**13. Fee Payment Being Made at This Time**

Not Enclosed

No filing fee is to be paid at this time.

*(This and the surcharge required by 37 C.F.R. Section 1.16(e) can be paid subsequently.)*

Enclosed

Filing fee \$ 770.00

Recording assignment  
(\$40.00; 37 C.F.R. Section 1.21(h))  
(See attached "COVER SHEET FOR  
ASSIGNMENT ACCOMPANYING NEW  
APPLICATION.")

Petition fee for filing by other  
than all the inventors or person  
on behalf of the inventor where  
inventor refused to sign or cannot  
be reached  
(\$130.00; 37 C.F.R. Sections 1.47 and 1.17(i))\$

For processing an application with a  
specification in a non-English language  
(\$130.00; 37 C.F.R. Sections 1.52(d) and 1.17(k))\$

Processing and retention fee  
(\$130.00; 37 C.F.R. Sections 1.53(d) and 1.21(l))\$

Fee for international-type search report  
(\$40.00; 37 C.F.R. Section 1.21(e)) \$

*NOTE: 37 C.F.R. Section 1.21(l) establishes a fee for processing and retaining any application that is abandoned for failing to complete the application pursuant to 37 C.F.R. Section 1.53(f) and this, as well as the changes to 37 C.F.R. Section 1.53*

*(New Application Transmittal page 7 of 9)*

and 1.78(a)(1), indicate that in order to obtain the benefit of a prior U.S. application, either the basic filing fee must be paid, or the processing and retention fee of Section 1.21(l) must be paid, within 1 year from notification under Section 53(j).

Total Fees Enclosed \$ \_\_\_\_\_

#### **14. Method of Payment of Fees**

Check in the amount of \$ 770.00.

Charge Account No. **04-1105** in the amount of \$ \_\_\_\_\_.

A duplicate of this transmittal is attached. .

**NOTE:** Fees should be itemized in such a manner that it is clear for which purpose the fees are paid. 37 C.F.R. Section 1.22(b).

**15. Authorization to Charge Additional Fees**

**WARNING:** If no fees are to be paid on filing, the following items should not be completed.

**WARNING:** *Accurately count claims, especially multiple dependent claims, to avoid unexpected high charges, if extra claim charges are authorized.*

The Commissioner is hereby authorized to charge any additional fees by this paper and during the entire pendency of this application to Account No. **04-1105**.

**16. Instructions as to Overpayment**

*NOTE: ". . . Amounts of twenty-five dollars or less will not be returned unless specifically requested within a reasonable time, nor will the payer be notified of such amounts; amounts over twenty-five dollars may be returned by check or, if requested, by credit to a deposit account." 37 C.F.R. Section 1.26(a).*

[X] Credit Account No. 04-1105.

[X] Refund Account No. 04-1105.

Date: October 30, 2003



**SIGNATURE OF PRACTITIONER**

Reg. No. 45,281

Dianne M. Rees, Ph.D.

*(type or print name of practitioner)*

Tel. No.: (617) 439-4444

EDWARDS & ANGELL, LLP

P.O. Box 9169

Boston, MA 02209

Customer No.: 21874

BOS2\_352392.1